MUC1
Mucin-1
Also known as: ADMCKD, ADMCKD1, Ca15-3, CD227, EMA, KL-6, MCD, MCKD, MCKD1, MUC1_HUMAN, PEM, PUM
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P15941
- Gene
- MUC1
- Ensembl
- ENSG00000185499
- Chromosome
- 1
- Canonical length
- 1255 aa
- Protein class
- Cancer-related genes, CD markers, Disease related genes, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins
- Subcellular location
- Plasma membrane
- Secretome location
- Secreted in other tissues
OverviewNCBI Gene
This gene encodes a membrane-bound protein that is a member of the mucin family. Mucins are O-glycosylated proteins that play an essential role in forming protective mucous barriers on epithelial surfaces. These proteins also play a role in intracellular signaling. This protein is expressed on the apical surface of epithelial cells that line the mucosal surfaces of many different tissues including lung, breast stomach and pancreas. This protein is proteolytically cleaved into alpha and beta subunits that form a heterodimeric complex. The N-terminal alpha subunit functions in cell-adhesion and the C-terminal beta subunit is involved in cell signaling. Overexpression, aberrant intracellular localization, and changes in glycosylation of this protein have been associated with carcinomas. This gene is known to contain a highly polymorphic variable number tandem repeats (VNTR) domain. Alternate splicing results in multiple transcript variants.[provided by RefSeq, Feb 2011]
Canonical amino-acid sequenceUniProt
1255 residues, UniProt reviewed canonical sequence.
>P15941|MUC1
1 MTPGTQSPFF LLLLLTVLTV VTGSGHASST PGGEKETSAT QRSSVPSSTE KNAVSMTSSV
61 LSSHSPGSGS STTQGQDVTL APATEPASGS AATWGQDVTS VPVTRPALGS TTPPAHDVTS
121 APDNKPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS
181 APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS
241 APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS
301 APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS
361 APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS
421 APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS
481 APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS
541 APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS
601 APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS
661 APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS
721 APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS
781 APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS
841 APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS
901 APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDNRPALGS TAPPVHNVTS
961 ASGSASGSAS TLVHNGTSAR ATTTPASKST PFSIPSHHSD TPTTLASHST KTDASSTHHS
1021 SVPPLTSSNH STSPQLSTGV SFFFLSFHIS NLQFNSSLED PSTDYYQELQ RDISEMFLQI
1081 YKQGGFLGLS NIKFRPGSVV VQLTLAFREG TINVHDVETQ FNQYKTEAAS RYNLTISDVS
1141 VSDVPFPFSA QSGAGVPGWG IALLVLVCVL VALAIVYLIA LAVCQCRRKN YGQLDIFPAR
1201 DTYHPMSEYP TYHTHGRYVP PSSTDRSPYE KVSAGNGGSS LSYTNPAVAA TSANLLocalizationUniProt · AlphaFold · HPA
Whether an antibody against MUC1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.41
- Highest tissue expression
- 998 nTPM
Expression across tissuesHPA
Tissue
- stomach: 998 nTPM
- kidney: 417 nTPM
- pancreas: 342 nTPM
- lung: 310 nTPM
- esophagus: 206 nTPM
- cervix: 182 nTPM
Single-cell type
- foveolar cells: 272 nCPM
- alveolar cells type 2: 236 nCPM
- breast lactating cells: 218 nCPM
- alveolar cells type 1: 193 nCPM
- transitional alveolar cells: 177 nCPM
- endometrial secretory cells: 155 nCPM
Immune cell
- T-reg: 1.2 nTPM
- memory CD4 T-cell: 0.6 nTPM
- basophil: 0.3 nTPM
- MAIT T-cell: 0.2 nTPM
- naive CD8 T-cell: 0.2 nTPM
- memory CD8 T-cell: 0.1 nTPM
Brain region
- medulla oblongata: 15 nTPM
- thalamus: 11 nTPM
- cerebral cortex: 10 nTPM
- midbrain: 8.8 nTPM
- pons: 8.2 nTPM
- spinal cord: 8 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about MUC1.
Disease | AllUniProt
Conditions MUC1 is implicated in, by any mechanism.
- Tubulointerstitial kidney disease, autosomal dominant 2 (ADTKD2) MIM:174000
Disease | GeneticClinVar
9 pathogenic / likely-pathogenic of 160 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Tubulointerstitial kidney disease, autosomal dominant, 2
Disease | ImmuneIEDB
Conditions an epitope on MUC1 was assayed in.
- colon carcinoma T cell
- breast cancer B and T cell
- multiple myeloma T cell
- prostate cancer T cell
- pancreatic ductal adenocarcinoma T cell
- ovarian cancer T cell
- castration-resistant prostate carcinoma T cell
- lung adenocarcinoma T cell
- lung non-small cell carcinoma T cell
- breast carcinoma T cell
- adenoma B cell
- ovarian serous carcinoma T cell
- prostate adenocarcinoma B cell
- myeloid leukemia T cell
- ovary epithelial cancer T cell
- colorectal cancer T cell
- renal carcinoma T cell
Disease | AutoantibodyPubMed
Conditions in which antibodies against MUC1 are reported. Each links to that disease's full target list.
Showing 3 of 4 — disease pages carrying at least 10 antigens.
ReferencesPubMed · IEDB
Publications for MUC1 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
25 publications
- A systematic review of humoral immune responses against tumor antigens.
2009 · Cancer Immunol Immunother · RCR 4.7 · 233 citations - Serum galectin-2, -4, and -8 are greatly increased in colon and breast cancer patients and promote cancer cell adhesion to blood vascular endothelium.
2011 · Clin Cancer Res · RCR 3.9 · 142 citations - Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma.
2023 · Clin Cancer Res · RCR 3.9 · 52 citations - Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer.
2003 · Int J Cancer · RCR 3 · 145 citations - Detection of Tumor-Associated Autoantibodies in the Sera of Pancreatic Cancer Patients Using Engineered MUC1 Glycopeptide Nanoparticle Probes.
2024 · Angew Chem Int Ed Engl · RCR 2.7 · 14 citations
Show 20 more
- Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer.
2000 · Am J Respir Crit Care Med · RCR 2.4 · 114 citations - Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates.
2000 · Vaccine · RCR 1.7 · 75 citations - Amplified Detection of Breast Cancer Autoantibodies Using MUC1-Based Tn Antigen Mimics.
2020 · J Med Chem · RCR 1.6 · 23 citations - The Use of Fluoroproline in MUC1 Antigen Enables Efficient Detection of Antibodies in Patients with Prostate Cancer.
2017 · J Am Chem Soc · RCR 1.5 · 37 citations - Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer.
2013 · Br J Cancer · RCR 1.5 · 48 citations - Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma.
2000 · Blood · RCR 1.5 · 68 citations - Cancer-associated autoantibodies to MUC1 and MUC4--a blinded case–control study of colorectal cancer in UK collaborative trial of ovarian cancer screening.
2014 · Int J Cancer · RCR 1.5 · 47 citations - An enzyme-linked immunosorbent assay for the measurement of circulating antibodies to polymorphic epithelial mucin (MUC1).
1998 · Tumour Biol · RCR 1.3 · 49 citations - Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer.
2011 · Cancer Immunol Immunother · RCR 1.3 · 47 citations - Tumour-Associated Autoantibodies as Diagnostic Biomarkers for Breast Cancer: A Systematic Review and Meta-Analysis.
2016 · Scand J Immunol · RCR 1.1 · 31 citations - Structure-Guided Approach for the Development of MUC1-Glycopeptide-Based Cancer Vaccines with Predictable Responses.
2024 · JACS Au · RCR 1 · 8 citations - A straightforward protocol for the preparation of high performance microarray displaying synthetic MUC1 glycopeptides.
2014 · Biochim Biophys Acta · RCR 0.9 · 29 citations - Detection of circulating anti-mucin 1 (MUC1) antibodies in breast tumor patients by indirect enzyme-linked immunosorbent assay using a recombinant MUC1 protein containing six tandem repeats and expressed in Escherichia coli.
2010 · Clin Vaccine Immunol · RCR 0.6 · 22 citations - Humoral immune response against tumoral mucin 1 (MUC1) in breast cancer patients.
2013 · Int J Biol Markers · RCR 0.4 · 13 citations - Malignancy-induced autoimmunity to MUC1: initial antibody characterization.
2005 · J Pept Res · RCR 0.3 · 11 citations - The immune response of mice and cynomolgus monkeys to macaque mucin 1-mannan.
2000 · Vaccine · RCR 0.2 · 12 citations - Autoantibodies against the signal peptide domain of MUC1 in patients with multiple myeloma: Implications for disease diagnosis and prognosis.
2012 · Exp Ther Med · RCR 0.2 · 6 citations - [Clinical significance of serum KL-6 in pulmonary sarcoidosis].
2001 · Nihon Kokyuki Gakkai Zasshi · RCR 0 · 1 citations - [Interstitial lung disease and lung cancer].
2010 · Gan To Kagaku Ryoho · RCR 0 · 1 citations - MUC1 as a diagnostic biomarker and siRNA-based therapeutic target in breast cancer: A clinical chemistry perspective.
2025 · Clin Chim Acta · 4 citations
Reference: B cellIEDB
4 publications
- Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma.
2023 · Clin Cancer Res · RCR 3.9 · 52 citations - Amplified Detection of Breast Cancer Autoantibodies Using MUC1-Based Tn Antigen Mimics.
2020 · J Med Chem · RCR 1.6 · 23 citations - The Use of Fluoroproline in MUC1 Antigen Enables Efficient Detection of Antibodies in Patients with Prostate Cancer.
2017 · J Am Chem Soc · RCR 1.5 · 37 citations - Impaired O-Glycosylation at Consecutive Threonine TTX Motifs in Mucins Generates Conformationally Restricted Cancer Neoepitopes.
2020 · Biochemistry · RCR 1.1 · 15 citations
Reference: T cellIEDB
25 publications
- Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival.
2012 · Nat Med · RCR 15.8 · 641 citations - Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer.
2018 · Clin Cancer Res · RCR 7.3 · 221 citations - Prediction of neo-epitope immunogenicity reveals TCR recognition determinants and provides insight into immunoediting.
2021 · Cell Rep Med · RCR 6.3 · 131 citations - Sensitive identification of neoantigens and cognate TCRs in human solid tumors.
2022 · Nat Biotechnol · RCR 4.9 · 84 citations - Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors.
2023 · Nat Commun · RCR 3.9 · 55 citations
Show 20 more
- Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis.
2015 · J Clin Invest · RCR 3.4 · 124 citations - Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer.
2019 · J Immunother Cancer · RCR 3.3 · 97 citations - A New Plasmacytoid Dendritic Cell-Based Vaccine in Combination with Anti-PD-1 Expands the Tumor-Specific CD8+ T Cells of Lung Cancer Patients.
2023 · Int J Mol Sci · RCR 1.8 · 20 citations - A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer.
2012 · Clin Exp Med · RCR 1.8 · 76 citations - Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma.
2005 · Blood · RCR 1.7 · 91 citations - Phase I/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, in multiple myeloma patients.
2015 · Br J Haematol · RCR 1.6 · 50 citations - Baseline immunity predicts prognosis of pancreatic cancer patients treated with WT1 and/or MUC1 peptide-loaded dendritic cell vaccination and a standard chemotherapy.
2021 · Hum Vaccin Immunother · RCR 1.5 · 28 citations - Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial.
2016 · Int J Oncol · RCR 1 · 33 citations - The shaping of a polyvalent and highly individual T-cell repertoire in the bone marrow of breast cancer patients.
2006 · Cancer Res · RCR 0.9 · 49 citations - Targeting DNGR-1 (CLEC9A) with antibody/MUC1 peptide conjugates as a vaccine for carcinomas.
2014 · Eur J Immunol · RCR 0.6 · 25 citations - Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: an exploratory study.
2014 · Hum Vaccin Immunother · RCR 0.5 · 19 citations - In vitro Generation of Cytotoxic T Cells With Potential for Adoptive Tumor Immunotherapy of Multiple Myeloma.
2019 · Front Immunol · RCR 0.5 · 13 citations - Identification and characterization of agonist epitopes of the MUC1-C oncoprotein.
2014 · Cancer Immunol Immunother · RCR 0.5 · 20 citations - Altered MUC1 epitope-specific CTLs: A potential target for immunotherapy of pancreatic cancer.
2022 · J Leukoc Biol · RCR 0.4 · 6 citations - Antigen specific T-cell responses against tumor antigens are controlled by regulatory T cells in patients with prostate cancer.
2012 · J Urol · RCR 0.4 · 20 citations - Downregulation of MUC1 expression and its recognition by CD8⁺ T cells on the surface of malignant pleural mesothelioma cells treated with HDACi.
2012 · Eur J Immunol · RCR 0.4 · 14 citations - Boost and loss of immune responses against tumor-associated antigens in the course of pregnancy as a model for allogeneic immunotherapy.
2015 · Blood · RCR 0.3 · 12 citations - Application of the pMHC Array to Characterise Tumour Antigen Specific T Cell Populations in Leukaemia Patients at Disease Diagnosis.
2015 · PLoS One · RCR 0.3 · 12 citations - Immunotherapy of lung adenocarcinoma patient with Peptide-pulsed dendritic cells: a case report.
2012 · Arch Immunol Ther Exp (Warsz) · RCR 0.2 · 8 citations - Expansion of quiescent lung adenocarcinoma CD8+ T cells by MUC1-8-mer peptide-T2 cell-β2 microglobulin complexes.
2016 · Oncol Rep · RCR 0.1 · 3 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.68
- gnomAD pLI
- 0.02
- gnomAD missense Z
- -1.23
- DepMap mean gene effect
- -0.18
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- DNA damage response, signal transduction by p53 class mediator
- mitotic G1 DNA damage checkpoint signaling
- negative regulation of cell adhesion mediated by integrin
- negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator
- negative regulation of transcription by competitive promoter binding
- positive regulation of transcription by RNA polymerase II
Molecular functions
- p53 binding
- RNA polymerase II cis-regulatory region sequence-specific DNA binding
- transcription coregulator activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of MUC1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads MUC1 as an antibody target. Whether an autoantibody or antibody against MUC1 could matter depends on whether native MUC1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
MUC1 is annotated at the cell surface, where native MUC1 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label MUC1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...